Rallybio Q1 net loss $9.4M; discontinues RLYB212, cuts workforce 40%

Rallybio Corp

2025-Q1 EPS reported -$0.21 revenue$212,000

Net loss $9.4M ($0.21 per share) vs $19.0M ($0.47) in Q1 2024; revenue $0.2M from J&J collaboration.
Cash, cash equivalents, and marketable securities $54.5M; runway into 1H 2027.
RLYB212 program discontinued after Phase 2 PK data missed target concentrations.
Workforce reduction of 40% (nine positions) with ~$1.7M in severance charges; substantially complete by end of Q2 2025.
RLYB116 confirmatory PK/PD study on track to start in Q2 2025; Cohort 1 data in Q3, Cohort 2 in Q4.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.